|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-590-5p functions as a tumor suppressor in breast cancer conferring inhibitory effects on cell migration, invasion, and epithelial-mesenchymal transition by downregulating the Wnt-β-catenin signaling pathway.
|
30191949 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
During the discovery step, three elevated miRNAs (miR‑15b‑5p, miR‑590‑5p, miR‑29b‑3p) and two decreased miRNAs (miR‑10b‑5p, miR‑144‑5p) were selected as potential miRNA candidates for further validation. miR‑15b‑5p and miR‑590‑5p were finally confirmed to discriminate between cancer cases and controls; however, for disease monitoring of BC, both miRNAs were not suitable as a decline in the miRNA levels was not observed in some patients after tumor removal.
|
31364733 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, miR-590-3p was downregulated and exerted a tumor-suppressive function in glioma cells.
|
31186064 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of miR-590 presented the negative correlation with PPM1F expression and acted as an independent prognostic factor for tumour recurrence in patients with GC.
|
29473240 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Inhibition of miR-590-5p suppressed tumor growth and metastasis in mouse xenograft and CRC liver metastasis models via inhibition of MMPs activity.
|
29247825 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study, miR‑590‑5p was identified to be upregulated in MM cells compared with human melanocytes using a reverse transcription‑quantitative polymerase chain reaction to screen established oncogenic and tumor suppressor miRNAs. miR‑590‑5p was demonstrated to inhibit the cell proliferation and tumor growth of MM cells in vitro and in vivo by performing Cell Counting Kit‑8 and tumour xenograft assays, respectively.
|
30106445 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, the expression level of serum miR-590 was correlated with pathological staging (P=0.022), lymph node metastasis (P=0.012), distant metastasis (P<0.001) and tumor, node and metastasis (TNM) staging (P=0.044).
|
29434870 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i> studies revealed that mir-590 accelerated tumor growth and metastasis.
|
29748371 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, <i>in vivo</i> xenograft models, the mice given stable overexpressed miR-590-3p cells and treated with EMAP-II and TMZ had the smallest tumor sizes, besides, miR-590-3p + EMAP-II + TMZ up-regulated the expression level of miR-590-3p, LC3-II and Beclin-1 as well as down-regulated p62/SQSTM1.
|
28348518 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of inositol polyphosphate 4-phosphatase type II could reduce microRNA-590-3p-induced cell proliferation and invasion as well as tumor growth, and decrease microRNA-590-3p-mediated upregulation of cyclin D1 and downregulation of p21 expression in prostate cancer cells.
|
28345464 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, gain-of-function and loss-of-function studies show miR-590 serve as a tumor suppressor regulating lung adenocarcinoma cells migration and invasion.
|
28012926 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate a tumor suppressor role of miR-590-3p in hepatocellular carcinoma through targeting transcriptional enhancer activator domain 1 and suggest its use in the diagnosis and prognosis of liver cancer.
|
28349829 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BRCA1/2 mutational status (p = 0.027), large tumor size (p = 0.041) and advanced histological grade (p = 0.017) among clinic-pathological variables; ER (p < 0.001) among IHC markers; MYC (p < 0.001) among CNA; APC (p = 0.065), ATM (p = 0.014) and RASSF1 (p = 0.044) among PM; and miR-590-5p (p = 0.001), miR-4417 (p = 0.019) and miR-423 (p = 0.013) among microRNA expression, were the selected parameters significantly related with the BRCAness status.
|
26723934 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data reveal miR-590 as a tumor suppressor in NSCLC, which is at least partially mediated through targeting of ADAM9.
|
27770372 |
2016 |